Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Ex-CDC director Tom Frieden on the state of COVID-19 vaccines

Ex-CDC director Tom Frieden on the state of COVID-19 vaccines

FromAxios Re:Cap


Ex-CDC director Tom Frieden on the state of COVID-19 vaccines

FromAxios Re:Cap

ratings:
Length:
14 minutes
Released:
Oct 13, 2020
Format:
Podcast episode

Description

Johnson & Johnson has paused Phase 3 trials for its COVID-19 vaccine candidate, after one patient reported an “unexplained illness.” This comes after AstraZeneca paused its Phase 3 trials due to an adverse event, and Moderna slowed its trial because of enrollment difficulties. Dan discusses these developments and more with Dr. Tom Frieden, who led the CDC between 2009 and 2017. Plus, Axios chief financial correspondent Felix Salmon joins to discuss official unemployment vs. “true” unemployment in the U.S.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Released:
Oct 13, 2020
Format:
Podcast episode

Titles in the series (100)

Each weekday afternoon, Axios business editor Dan Primack unpacks the biggest story of the day and why it matters. In 10 minutes, Dan and his guests - global business leaders, influential political operators, and reporters chasing huge scoops - take you inside the accelerating forces, technologies and trends that are remaking your world and work.  About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app  About Dan Primack: Dan is the host of Axios Re:Cap. He is also a business editor at Axios and author of the daily Axios Pro Rata newsletter where he covers the world of dealmakers across VC, PE and M&A. Previously, he was a senior editor at Fortune magazine and Thomson Reuters.